Document is current
Any future updates will be listed below
-
Authors
de Smet, Marc D. http://orcid.org/0000-0002-9217-5603
Goncerut, Matthieu
Asmus, Friedrich
Yamamoto, Ron
- License Information
-
More Information
Article History
Received: 13 June 2023
Accepted: 22 August 2023
First Online: 5 September 2023
Declarations
:
: All experiments were performed in accordance with relevant guidelines and regulations (such as the Declaration of Helsinki). The need for ethical approval was waived by the regional medical ethics committee of the canton of Vaud (d’éthique médicale du canton de Vaud, CEMV), as Triesence was approved for use in Switzerland. Approval for the use of the Oxulumis device was obtained from SwissMedic under the provision that it is used with an approved medical product. All patients provided written informed consent.
: All patients provided written informed consent for publication.
: MdS is a consultant for Oxular; FA and RY are employees of Oxular Ltd; MG has no financial disclosures.
